CurrentEvolentPolicy N/A

Evolent Heart Catheterization

Customize your policy alerts

Sign up for all evolent policy alerts

Know when evolent releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy tip sheet summarizes clinical situations in which Evolent considers heart catheterization medically appropriate and identifies documentation needed for review. It applies to providers requesting authorization for coronary angiography and related hemodynamic assessment, while noting that stand-alone right heart catheterization is not managed by Evolent.

Policy Summary

PayerEvolent

PolicyHeart Catheterization

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit supporting documentation, reports, and testing with the authorization request.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5 yearsAnnual graft vasculopathy assessment period

≥50%Left main stenosis threshold

<0.8FFR-CT threshold

<35%Resting LVEF threshold

≥10%

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentEvolentPolicy N/A

Evolent Heart Catheterization

Customize your policy alerts

Sign up for all evolent policy alerts

Know when evolent releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerEvolent

PolicyHeart Catheterization

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit supporting documentation, reports, and testing with the authorization request.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5 yearsAnnual graft vasculopathy assessment period

≥50%Left main stenosis threshold

<0.8FFR-CT threshold

<35%Resting LVEF threshold

≥10%

When Heart Catheterization Is Medically Appropriate

Stable Ischemic Heart Disease

Heart catheterization is recommended for stable ischemic heart disease when any of the following circumstances applies.

Stable ischemic heart disease indications

Symptoms with inability to perform noninvasive testing: Symptoms of ischemia; the patient cannot undergo stress testing or CCTA; and there is a high likelihood that the result will affect therapy.
High-risk exercise treadmill findings: ETT with high-risk DTS, ST elevation, hypotension, ventricular tachycardia during exercise, or several minutes of ST depression persisting into recovery.DTS -11
Low-risk stress imaging with persistent symptoms: Low-risk stress imaging with new or worsening symptoms concerning for coronary origin despite optimal medical therapy, or documentation that the patient cannot tolerate optimal medical therapy.
Intermediate-risk stress imaging: Intermediate-risk findings on stress imaging with symptoms suggestive of CAD, unsatisfactory quality of life due to angina symptoms, or EF less than 50%.EF <50%
High-risk stress imaging: Resting LV dysfunction, severe stress-induced LV dysfunction, stress-induced perfusion abnormalities, stress involving multiple vascular territories, or stress-induced LV dilation.Resting LVEF <35%; stress-induced perfusion abnormality ≥10% of myocardium
Discordant or inconclusive noninvasive results: The patient is symptomatic and noninvasive results are discordant or inconclusive, such as a strongly positive stress ECG portion with low-risk imaging.

CCTA Abnormalities

Heart catheterization is recommended for symptomatic CCTA abnormalities or significant left main disease when any of the following applies.

CCTA abnormality indications

One-vessel stenosis: The patient is symptomatic and has one vessel with greater than 50% stenosis.>50% stenosis
Stenosis with abnormal FFR-CT: The patient is symptomatic and has stenosis of 40%-90% with FFR-CT less than 0.8.40%-90% stenosis; FFR-CT <0.8
Left main stenosis is 50% or greater, regardless of symptoms.≥50% stenosis

Heart Failure and Left Ventricular Dysfunction

For patients who are candidates for coronary revascularization, heart catheterization is recommended when any of the following heart failure or left ventricular dysfunction indications applies.

Heart failure and left ventricular dysfunction indications

Newly recognized heart failure in a patient with known or suspected CAD.
New wall motion abnormality and symptoms suggestive of ischemia.
Structural heart disease with possible ischemic etiology: Investigation of structural heart disease when there is concern for an ischemic etiology, including secondary MR or VSD.
Diastolic heart failure etiology: Investigation of the etiology of diastolic heart failure when there is a reasonable likelihood of CAD based on symptoms or imaging studies.

Ventricular Arrhythmias

For ventricular arrhythmias without an identified non-cardiac cause, heart catheterization is recommended when any of the following applies.

Ventricular arrhythmia indications

Recovery after cardiac arrest: Recovery post cardiac arrest.
Sustained ventricular tachycardia or fibrillation: Sustained ventricular tachycardia or ventricular fibrillation.
Exercise-induced ventricular tachycardia.

Before Non-Coronary Cardiac Surgery

Before non-coronary cardiac surgery, heart catheterization is recommended when the patient has the planned surgery and any one of the following clinical or testing factors.

Preoperative non-coronary cardiac surgery

Preoperative risk or anatomy factors: Symptoms of angina; history of CAD or cardiac risk factors, including men older than 40 or postmenopausal women; LV function less than 50%; prior to TAVR; noninvasive data showing objective evidence of ischemia; or need for more detailed assessment of coronary anatomy, including anomalous origins.LV function <50%; men >40 years

Post Cardiac Transplantation

After cardiac transplantation, heart catheterization is recommended for either scheduled graft vasculopathy surveillance or a clinical change.

Post-cardiac-transplantation indications

Graft vasculopathy surveillance: Assessment for annual graft vasculopathy during the first 5 years after transplantation, followed by annual assessment if documented allograft vasculopathy is present.Annual assessment for the first 5 years
Clinical change after transplantation: A clinical change occurs, including new LV dysfunction, ischemic symptoms, or noninvasive findings of ischemia.

Hemodynamic Assessment

Hemodynamic assessment is recommended when either of the following circumstances applies.

Hemodynamic assessment indications

Discordance requiring management change: There is discordance between noninvasive data and the clinical picture, and management will be changed by the angiogram results.
Prosthetic valve assessment with inadequate imaging: Hemodynamic assessment of a bioprosthetic or mechanical valve is needed; TTE and TEE images are inadequate; and CMR or CCT are not readily available.

Evolent does not manage right heart catheterization as a stand-alone procedure.

Clinical Thresholds and Risk Factors

Resting left ventricular ejection fraction

Threshold<35% resting left ventricular ejection fraction

Stress-induced myocardial perfusion abnormality

Threshold≥10% of myocardium

Symptomatic coronary stenosis with FFR-CT

Stenosis range40%-90%

FFR-CT threshold<0.8

Documentation and Clinical Review Requirements

Prior Authorization

Apply Evolent guidelines and support the request

Use the applicable Evolent clinical guidelines when reviewing medical necessity and clinical appropriateness. Provide supporting documentation, reports, and testing with the request.

Documentation Required

Submit clinical records and testing

Submit documentation, reports, and testing for review. Office notes should explain the plan for arteriography and relate it to an increasing pattern of typical symptoms concerning for unstable angina.

Policy Context

Heart catheterization is considered for evaluation of suspected or known coronary artery disease when symptoms, noninvasive testing, ventricular dysfunction, arrhythmia, planned cardiac surgery, transplantation status, or discordance between clinical findings and noninvasive results supports invasive assessment. The procedure is generally considered when results are expected to affect treatment, revascularization decisions, or further structural and hemodynamic evaluation.